Earnings summaries and quarterly performance for Atea Pharmaceuticals.
Executive leadership at Atea Pharmaceuticals.
Jean-Pierre Sommadossi
Detailed
President and Chief Executive Officer
CEO
AC
Andrea Corcoran
Detailed
Chief Financial Officer, Executive Vice President, Legal, and Secretary
JH
Janet Hammond
Detailed
Chief Development Officer
JV
John Vavricka
Detailed
Chief Commercial Officer
MH
Maria Horga
Detailed
Chief Medical Officer
WF
Wayne Foster
Detailed
Executive Vice President and Chief Accounting Officer
Board of directors at Atea Pharmaceuticals.
Research analysts who have asked questions during Atea Pharmaceuticals earnings calls.
TH
Tsan-Yu Hsieh
William Blair & Company
2 questions for AVIR
Also covers: CRDF, EXEL, FGEN +6 more
IC
Isabella Camaj
Evercore ISI
1 question for AVIR
Also covers: ALKT
Jonathan Miller
Evercore ISI
1 question for AVIR
Also covers: APLS, ARVN, ATRA +8 more
KL
Kelsey Lucerne
William Blair & Company
1 question for AVIR
MS
Maxwell Skor
H.C. Wainwright & Co.
1 question for AVIR
Also covers: ASND, CRNX, CYTK +4 more
Recent press releases and 8-K filings for AVIR.
Atea Pharmaceuticals Provides Updates on Hepatitis C Phase 3 Program and New Hepatitis E Candidate
AVIR
New Projects/Investments
Product Launch
Guidance Update
- Atea Pharmaceuticals' global Phase 3 program for Hepatitis C is on track, with results for the North American trial (CB-ARC) expected mid-2026 (Q3) and for the C-FORWARD trial by end of 2026 (Q4), leading to an anticipated NDA filing in Q1 2027.
- The company has selected 80587 as a clinical candidate for its new Hepatitis E program, with a CTA filing in Europe planned for Q2 2026 and initiation of a proof-of-concept study by end of 2026, targeting a billion-dollar market opportunity with no current treatment.
- Atea maintains a solid balance sheet with over $300 million in cash and investments as of late December, providing a cash runway through 2027 and into early 2028, sufficient to complete its Phase 3 programs.
- The Hepatitis C regimen, combining bemnifosbuvir and ruzasvir, demonstrated 98% efficacy in Phase 2 and is positioned as a best-in-class profile for a billion-dollar market, with commercial launch readiness underway for late 2027 or early 2028.
Jan 15, 2026, 3:30 PM
Atea Pharmaceuticals Provides Pipeline Update and Financial Outlook
AVIR
New Projects/Investments
Guidance Update
Product Launch
- Atea Pharmaceuticals reported cash and investments of $301.8 million as of December 31, 2025, with an anticipated cash runway through 2027.
- For its BEM/RZR regimen for Hepatitis C Virus (HCV), the Phase 3 C-BEYOND trial (US/Canada) has completed enrollment with results expected mid-2026. Enrollment for the C-FORWARD trial (outside North America) is expected to complete by mid-2026, with results by year-end 2026, and an NDA submission anticipated in Q1 2027.
- In Phase 2, the BEM/RZR regimen demonstrated 98% sustained virologic response at 12 weeks post-treatment (SVR12).
- For its Hepatitis E Virus (HEV) program, Atea targets Phase 1 initiation for AT-587 in mid-2026 , addressing a potential commercial opportunity of $750 million to $1 billion in the US & EU.
Jan 15, 2026, 3:30 PM
Atea Pharmaceuticals Details Hepatitis C Phase III Progress and New Hepatitis E Program
AVIR
New Projects/Investments
Guidance Update
Product Launch
- Atea Pharmaceuticals anticipates top-line Phase III results for its Hepatitis C treatment, CB-ARC, in Q3 2026. Enrollment for the C-FORWARD trial is expected to complete in Q2 2026, with results by Q4 2026, leading to an NDA filing in Q1 2027.
- The company has selected AT-587 as a clinical candidate for its new Hepatitis E program, with an IND/CTA filing expected in Q2 2026 and initiation of a proof-of-concept study by the end of 2026.
- Atea maintains a strong financial position with over $300 million in cash and investments as of late December, providing a cash runway through 2027 and into early 2028.
- Both the Hepatitis C regimen and the new Hepatitis E program are considered billion-dollar commercial opportunities, with the Hepatitis C treatment expected to achieve profitability within 24 months post-launch.
Jan 15, 2026, 3:30 PM
Atea Pharmaceuticals Provides Updates on Hepatitis C Phase 3 Program and New Hepatitis E Program
AVIR
New Projects/Investments
Guidance Update
Product Launch
- Atea Pharmaceuticals anticipates top-line Phase 3 results for its Hepatitis C (HCV) regimen, bemnifosbuvir and ruzasvir, from the CB-ARC trial in Q3 2026 and from the C-FORWARD trial by the end of 2026, with an NDA filing projected for Q1 2027.
- The company has selected 80587 as a clinical candidate for its new Hepatitis E (HEV) program, planning to file a CTA in Europe in Q2 2026 and initiate a proof-of-concept study by the end of 2026.
- Atea Pharmaceuticals reports a strong financial position with over $300 million in cash and investments, providing a cash runway through 2027 and into early 2028.
- The company projects its HCV regimen to be a billion-dollar drug and views its HEV program as another billion-dollar opportunity.
Jan 15, 2026, 3:30 PM
Atea Pharmaceuticals Highlights 2026 Strategic Priorities and Financial Position
AVIR
Guidance Update
New Projects/Investments
- Atea Pharmaceuticals ended 2025 with $301.8 million in cash and investments, providing a cash runway expected to extend through 2027.
- The company anticipates mid-2026 for topline results from its North American Phase 3 C-BEYOND trial for Hepatitis C virus (HCV) and year-end 2026 for results from the C-FORWARD trial outside North America.
- Atea plans to initiate a Phase 1 clinical program for its Hepatitis E virus (HEV) product candidate, AT-587, in mid-2026.
- The global HCV market is estimated at approximately $3 billion in net sales annually, with the US accounting for about $1.5 billion. The potential US and EU commercial market opportunity for HEV is estimated at $750 million to $1 billion.
Jan 8, 2026, 2:05 PM
Atea Pharmaceuticals Provides Clinical and Financial Updates
AVIR
Product Launch
New Projects/Investments
Guidance Update
- Atea Pharmaceuticals announced significant progress in its Hepatitis C (HCV) program, with the Phase III C-BEYOND study in North America having completed patient screening and nearing full enrollment of 880 patients, with results anticipated by mid-2026. The C-FORWARD study is also progressing, with full enrollment expected by mid-2026 and results by the end of 2026. The company aims to file an NDA in Q1 2027.
- The company is advancing its Hepatitis E (HEV) program with candidates AT-587 and AT-2490, targeting immunocompromised patients for whom there is currently no approved treatment. This program represents a potential market opportunity of $500 million to $750 million annually in the U.S. and Europe. A proof-of-concept study is slated for mid-2026, with results expected in 2027, followed by Phase II/III trials in 2027.
- Atea Pharmaceuticals maintains a strong financial position, reporting nearly $330 million in cash at the end of September, which is projected to fund operations through the end of 2027 or early 2028, covering the full delivery of its hepatitis C program.
Dec 3, 2025, 3:00 PM
Atea Provides Updates on Hepatitis C and E Programs, Financial Runway
AVIR
Product Launch
New Projects/Investments
Guidance Update
- Atea (AVIR) announced the achievement of its patient recruitment target for the Phase 3 CBONC study for Hepatitis C in North America, with enrollment of 880 patients anticipated to be completed soon and results expected in mid-2026. The C-FORWARD study is also recruiting well, with results by the end of 2026.
- The company reported a solid balance sheet of almost $330 million at the end of September, providing financial runway through the end of 2027 or early 2028.
- Atea plans to file the New Drug Application (NDA) for its Hepatitis C program in Q1 2027. For launch (2027/2028), Atea expects competitive pricing and will have 20,000 to 30,000 treatments immediately available.
- Atea is advancing new Hepatitis E assets (AT-587/AT-2490) targeting a $500-750 million annual market for immunocompromised patients, with Phase 1 expected in mid-2026 and Phase 2/3 in 2027.
Dec 3, 2025, 3:00 PM
Atea Pharmaceuticals Provides Updates on Hepatitis C and E Programs, Financial Runway
AVIR
New Projects/Investments
Guidance Update
Product Launch
- Atea Pharmaceuticals has achieved its patient recruitment target for the Phase 3 CBONC study in North America, with enrollment of 880 patients expected to be completed soon and results anticipated by mid-2026. The C-FORWARD study outside North America is also recruiting well, with full enrollment expected around mid-2026 and results by the end of 2026.
- The company announced new drug candidates, AT-587 and AT-2490, for Hepatitis E, targeting immunocompromised patients with a potential market opportunity of $500-750 million in the U.S. and Europe, aiming for 15,000 patients annually. Phase 1 for this program is expected in mid-2026, with proof of concept by end of 2026 and Phase 2/3 starting in 2027.
- Atea Pharmaceuticals reported a solid balance sheet with almost $330 million at the end of September, providing financial runway through the end of 2027 or beginning of 2028.
- The company believes the Hepatitis C market is growing, with 150,000 new cases annually in the U.S. versus 100,000 treated, and plans a commercial launch with 20,000 to 30,000 treatments immediately available by the time of launch in 2027-2028, with competitive pricing.
Dec 3, 2025, 3:00 PM
AVIR Provides Update on Phase 3 Hepatitis C Program and Market Research
AVIR
New Projects/Investments
Product Launch
- AVIR is advancing its global Phase 3 program for the chronic hepatitis C regimen, bemnifosbuvir and ruzasvir, which is being compared against the current standard of care.
- The regimen achieved a 98% sustained virologic response (SVR12) in Phase 2 studies and is differentiated by a short treatment duration (predicted cure time of seven to eight weeks) and a low risk for drug-drug interactions, including with proton pump inhibitors.
- Enrollment for the North American CBEYOND trial is expected to complete next month (December 2025), with top-line results anticipated mid-2026; enrollment for the CFORG trial is expected to complete mid-2026, with top-line results by year-end 2026.
- Quantitative market research indicated that 76% of top US DAA prescribers were "extremely likely to prescribe" the regimen, expecting to use it in approximately half their patients.
- The regimen's unique dual mechanism of action for bemnifosbuvir and its potential for a single, full-course dispense are highlighted as key advantages for patient adherence and economic value as a "cost of cure".
Nov 13, 2025, 3:00 PM
Atea Pharmaceuticals Reports Q3 2025 Financials and Provides Clinical Pipeline Updates
AVIR
Earnings
New Projects/Investments
Guidance Update
- Atea Pharmaceuticals reported cash, cash equivalents, and marketable securities of $329.3 million as of September 30, 2025, with an anticipated cash runway through 2027.
- For Q3 2025, the company reported a net loss of $(42,049) thousand and a net loss per share of $(0.53).
- Full patient enrollment for the Phase 3 C-BEYOND trial (US/Canada) for its HCV treatment is expected by year-end 2025 with results anticipated mid-2026, while the C-FORWARD trial (outside North America) expects full enrollment mid-2026 with results year-end 2026.
- Atea is expanding its antiviral pipeline into Hepatitis E Virus (HEV) with Phase 1 initiation targeted for mid-2026, addressing an estimated $500-750 million market opportunity in the US & EU.
Nov 12, 2025, 9:30 PM
Quarterly earnings call transcripts for Atea Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more